Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

Phase 2

Recruiting

Conditions: Circulatory Disease

Interventions: Drug: H001 Capsule 200mg-qd
Drug: H001 Capsule 300mg-qd
Drug: H001 Capsule 200mg-bid
Drug: Enoxaparin Sodium Injection

First Posted Date: 2025-05-09

Last Posted Date: 2025-05-09

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 320

Registration Number: NCT06963320

Locations: 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China

Phase III Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 3

Recruiting

Conditions: Prevention of Arterial and Venous Thrombosis

Interventions: Drug: SHR-2004 injection
Drug: Enoxaparin sodium injection
Drug: Enoxaparin sodium injection placebo
Drug: SHR-2004 placebo

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-02

Lead Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

Target Recruit Count: 1167

Registration Number: NCT06825416

Locations: 🇨🇳
Fourth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China

Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis

Phase 2

Not yet recruiting

Conditions: Portal Vein Thrombosis
Liver Cirrhosis

Interventions: Drug: Enoxaparin
Drug: Dabigatran

First Posted Date: 2025-02-10

Last Posted Date: 2025-02-10

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 120

Registration Number: NCT06818279

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.

Phase 2

Completed

Conditions: Fractures, Bone
CKD Stage 4
CKD Stage 3
CKD Stage 5
Enoxaparin Adverse Reaction
Anticoagulant-induced Bleeding
Thromboses, Venous

Interventions: Drug: Enoxaparin

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Hospital Civil de Guadalajara

Target Recruit Count: 61

Registration Number: NCT06795698

Locations: 🇲🇽
Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

Not Applicable

Recruiting

Conditions: Morbid Obesity
Bariatric Surgery Candidate

Interventions: Drug: Enoxaparin
Drug: rivaroxaban

First Posted Date: 2024-11-14

Last Posted Date: 2025-04-22

Lead Sponsor: Alexandria University

Target Recruit Count: 162

Registration Number: NCT06689241

Locations: 🇪🇬
Alexandria University, Alexandria, Egypt

Efficacy of Aspirin in Preventing Venous Thromboembolism

Phase 4

Completed

Conditions: Venous Thromboembolism (VTE)
Total Joint Arthroplasty
Total Hip Arthroplasty (THA)

Interventions: Drug: Aspirin
Drug: enoxaparin

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-10

Lead Sponsor: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Target Recruit Count: 60

Registration Number: NCT06635317

Locations: 🇲🇽
ISSSTEP, Puebla, Mexico

Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency

Phase 2

Not yet recruiting

Conditions: Pregnancy Related
Protein S Deficiency

Interventions: Drug: Enoxaparin
Drug: Aspirin

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 48

Registration Number: NCT06531525

Locations: 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing/Beijing, China

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Phase 1

Recruiting

Conditions: Coagulation Disorder

Interventions: Drug: VMX-C001
Drug: Enoxaparin
Drug: Rivaroxaban
Drug: UFH

First Posted Date: 2024-07-24

Last Posted Date: 2025-03-30

Lead Sponsor: VarmX B.V.

Target Recruit Count: 16

Registration Number: NCT06517563

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: REGN7508
Drug: Enoxaparin

First Posted Date: 2024-06-12

Last Posted Date: 2025-01-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 179

Registration Number: NCT06454630

Locations: 🇧🇬
Multi-profile Hospital for Active Treatment Hearth and Brain EAD, Pleven, Bulgaria
🇧🇬
Multiprofile Hospital For Active Treatment Park Hospital Ltd., Plovdiv, Bulgaria
🇭🇺
Budai Irgalmasrendi Korhaz, Budapest, Hungary

and more 11 locations

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

Phase 4

Recruiting

Conditions: Bleeding
Respiratory Insufficiency
Circulatory Failure
Thromboembolism

Interventions: Drug: Enoxaparin Injectable Solution
Drug: Unfractionated heparin
Drug: Argatroban, 1 Mg/mL Intravenous Solution

First Posted Date: 2024-06-04

Last Posted Date: 2024-10-29

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 90

Registration Number: NCT06442267

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy